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The Pseudomonas aeruginosa pathogen is found in soil, plants and hospital 
water reservoirs which include showers, sinks and toilet water. It is 
responsible for numerous human deaths each year due to its multidrug 
resistance (MDR) and is a significant threat to the immunocompromised and 
critically ill patients in healthcare settings. There has been a decline in 
breakthroughs in conventional medicine for the treatment of P. aeruginosa, 
but recent studies suggest finding new and novel treatment approaches, 
such as combining different types of antibiotics or pioneering innovative 
options, in treating infections related to P. aeruginosa. The administering of 
combination drugs is complex and in many instances have serious side 
effects, hence alternative therapeutic approaches are being explored. 
Phytotherapy and homeopathy are science-based medical practices that 
both make use of administering specially prepared plant-based medicines 
to treat patients. These modalities have shown that various plant-based 
medications have antimicrobial action without side-effects. The medicinal 
value of Psidium guajava L. (guava) has been reported in the treatment of 
various illnesses. It is known for its antispasmodic, anti-inflammatory, 
antimicrobial and anti-diarrhoeal properties due to the high ascorbic acid 
and tannins composition.  
The aim of this study was to determine the potential antimicrobial effect of 
Psidium guajava (P. guajava) L. herbal extract (HE), mother tincture (Ø) and 
3cH homeopathic potency, on 26 strains of multidrug resistant P. 
aeruginosa strains. This organism was chosen as it poses a serious threat 
in nosocomial infections and is extremely difficult to treat. 
The study was done by means of the Kirby-Bauer Disk Diffusion, Minimum 
Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), 
Agar Overlay Disk Diffusion and the Erlenmeyer methods according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines with antibiotics 
as positive control.  




The results demonstrated that Psidium guajava Ø was found to have 
antimicrobial actions against multidrug resistant P. aeruginosa by inhibiting 
growth of the organism in both liquid and solid culture media as well as 
surfing presenting in some cases. More testing needs to be done to 
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LIST OF ABBREVIATIONS 
Ø      Mother tincture 
1D     First decimal potency 
2D     Second decimal potency 
1cH     First centesimal potency 
2cH      Second centesimal potency 
3cH      Third centesimal potency 
ATCC     American Type Culture Collection 
CLSI      Clinical and Laboratory Standards Institute 
COPD    Chronic Obstructive Pulmonary Disease 
DNA     Deoxyribonucleic acid 
ED     Etner-Duodoroff 
EtOH     Ethanol 
FFDLPG  Flavanoid Fraction of Dried Leaves of Psidium 
guajava 
GHP     German Homoeopathic Pharmacopoeia 
HE     Herbal Extract 
I     Intermediate 
ICU     Intensive Care Units 
INT     Iodonitrotetrazolium chloride 
IV     Intravenous 
LPS     Lipopolysaccharides 
MBC     Minimum Bactericidal Concentration 
MDR     Multidrug resistance 
MIC     Minimum Inhibitory Concentration 
mRNA    Messenger Ribonucleic acid 
NADPH    Nicotinamide adenine dinucleotide phosphate 
NRF     National Research Foundation 
P. aeruginosa   Pseudomonas aeruginosa 
P. guajava    Psidium guajava 
PBP3     Penicillin Binding Protein 3 




PCP     Phencyclidine 
PSI     Pound per Square Inch 
R     Resistant 
RPM     Rotations per Minute 
S     Sensitive 
TFDLPG   Tannic Fraction of Dried Leaves of Psidium 
guajava 
tRNA     Transport Ribonucleic acid 
UPLC-ESI-QTOF-MS   Ultra-high performance liquid chromatography 
coupled with electrospray ionization-
quadrupole-time of flight-mass spectrometry 
UV     Ultraviolet 
WHRC    Water and Health Research Centre 
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1.1  Problem Statement 
Bacteria acquire multidrug resistance (MDR) by mutations that occur in the 
cells’ deoxyribonucleic acid (DNA) during replication and also through 
horizontal gene transfer (Lambert, 2002; Livermore, 2002; Nadal Jimenez 
et al., 2012; Gellatly and Hancock, 2013). Overuse of antibiotics and non-
compliance of patients to medication regimens due to adverse side effects, 
further contribute to MDR of bacteria (NIH, 2011). As a consequence, 
society has entered a phase where antibiotics have been overused and 
overprescribed and bacteria have developed MDR to most antibiotics in use 
(Strateva and Yordanov, 2009; Rasamiravaka et al., 2015; Moradali et al., 
2017). 
Pseudomonas aeruginosa (P. aeruginosa) is a non-fermentative, Gram-
negative opportunistic pathogen that causes nosocomial and community-
acquired infections (Calgin and Cetinkol, 2018; Hsueh et al., 2018). P. 
aeruginosa is found in soil, plants and hospital water reservoirs, which 
include showers, sinks and toilet water (Jefferies et al., 2012). The organism 
is responsible for numerous human deaths each year due to its MDR and 
is a significant threat to the immunocompromised and critically ill patients in 
healthcare settings, especially in intensive care units (ICU) (Strateva and 
Yordanov, 2009; Rasamiravaka et al., 2015; Moradali et al., 2017). The 
complications of P. aeruginosa infection include pneumonia, particularly 
ventilator-associated pneumonia, blood and urinary tract infections, wound 
infections and meningitis (Calgin and Cetinkol, 2018; Subramaniyan and 
Sundaram, 2018; Jain et al., 2019; Nawfal Dagher et al., 2019). Infections 
are linked to a very high rate of morbidity, mortality and related increased 
costs in the treatment of patients who are infected and require a longer stay 
in hospital or period of rehabilitation (Tiwari et al., 2015). A significant issue 




is a chance of organisms spreading, by means of an infected person to 
society, generating a wider issue than can currently be dealt with (Zhu et 
al., 2014; Karlowsky et al., 2017; Singh, 2018).  
P. aeruginosa has shown resistance to penicillin G; aminopenicillin, 
including those combined with beta-lactamase inhibitors; first and second 
generation cephalosporins; piperacillin; piperacillin and tazobactam; 
cefepime; ceftazidime; aminoglycosides; the quinolones; and the 
carbapenems; as well as colistin and fosfomycin (Yayan et al., 2015).  
There has been a decline in breakthroughs in conventional medicine for the 
treatment of P. aeruginosa (Boucher et al., 2013), but recent studies 
suggest finding new and novel treatment approaches, such as combining 
different types of antibiotics, in addressing infections related to P. 
aeruginosa  (de Breij et al., 2018; El Chakhtoura et al., 2018; Pletzer et al., 
2018). Due to the way the combination drugs have to be administered and 
the serious side effects they cause, there is a need to find new and 
alternative therapeutic approaches (Yayan et al., 2015). Phytotherapy has 
also shown that various plant-based medications have antimicrobial action 
without side-effects. The medicinal value of Psidium guajava L. (guava) has 
been reported in the treatment of various illnesses and is known for its anti-
spasmodic, anti-inflammatory, anti-microbial and anti-diarrhoeal properties 
(Gonçalves et al., 2008; Odugbemi et al., 2008; Biswas et al., 2013). 
1.2 Aim of the study 
The aim of this study was to investigate the potential antimicrobial effect of 
Psidium guajava (P. guajava) L. herbal extract (HE), mother tincture (Ø) and 
3cH homeopathic dilution on multidrug resistant P. aeruginosa strains.  
 




1.3 Objective of the study 
1) To determine if P. guajava L. herbal extract, homeopathic mother 
tincture and 3cH potency have anti-microbial effects on multidrug 
resistant P. aeruginosa strains using the Kirby Bauer disc diffusion 
method. 
2) To determine the minimum inhibitory concentration (MIC) of the P. 
guajava L. herbal extract, homeopathic mother tincture and 3cH 
potency on multidrug resistant P. aeruginosa strains. 
3) To determine if the P. guajava L. herbal extract, homeopathic mother 
tincture and 3cH potency on multidrug resistant P. aeruginosa strains 
have bactericidal or bacteriostatic effects on the multidrug resistant 
P. aeruginosa strains. 
1.4 Hypothesis 
It was hypothesized that the herbal extract, homeopathic mother tincture 
and 3cH potency of Psidium guajava L. would show antimicrobial actions 
against multidrug resistant Pseudomonas aeruginosa by inhibiting the 
growth of the organisms on solid and liquid culture medias. 
1.5 Null hypothesis 
The null hypothesis proposed that the herbal extract, homeopathic mother 
tincture and 3cH potency of Psidium guajava L. would not show 
antimicrobial actions against multidrug resistant P. aeruginosa by inhibiting 
the growth of the organisms on solid and liquid culture medias. 
2.      LIMITATIONS  
Certain limitations were experienced during this study and were all linked to 
additional tests that would have further contributed to the outcome of the 
work. These could not be done due to time and cost limitations. Some of 
these limitations are highlighted below: 




● Only five strains were selected as a sample for the Agar Overlay Disk 
Diffusion method and the Erlenmeyer Flask method due to time 
constraints. It is recommended that future studies be done using these 
two methods to compare the Kirby-Bauer Disk Diffusion method and 
Minimum Inhibitory Concentration methods for accurate results 
regarding the effectiveness of a tincture/extract without having a 
biofilm possibly influence results and give a false-positive or negative 
finding. 
● It would be beneficial to test if the P. aeruginosa cells were using efflux 
pumps, by  using a method such as the ethidium bromide test, which 
utilises an intercalating agent commonly used as a fluorescent tag 
(nucleic acid stain) in molecular biology laboratories, as reported by 
Shrestha et al. (2020). 
● A further limitation is that statistical analysis could not be done due to 
the biofilm which skewed and flawed the results. 
  





2. LITERATURE REVIEW 
2.1 Introduction 
Pseudomonas aeruginosa (P. aeruginosa) is a non-fermentative, Gram-
negative opportunistic pathogen that causes nosocomial and community-
acquired infections (Calgin and Cetinkol, 2018; Hsueh et al., 2018). 
Infections are linked to a very high rate of morbidity, mortality and related 
increased costs in the treatment of patients requiring a longer stay in 
hospital or period of rehabilitation (Tiwari et al., 2015). There has been a 
decline in breakthroughs in conventional medicine for the treatment of P. 
aeruginosa (Boucher et al., 2013), but recent studies suggest finding new 
and novel treatment approaches in addressing infections related to P. 
aeruginosa  (de Breij et al., 2018; El Chakhtoura et al., 2018; Pletzer et al., 
2018). 
2.2 Pseudomonas aeruginosa 
2.2.1 Classification of P. aeruginosa  
The species P. aeruginosa belongs to the Kingdom BACTERIA, 
Subkingdom Negibacteria, Phylum Proteobacteria, Class 
Gammaproteobacteria, Order Pseudomonadales, Family 
Pseudomonadaceae, and Genus Pseudomonas (Itis.gov, 2020). The class 
Gammaproteobacteria is Gram-negative, complex, large class that consists 
of 14 orders and 28 families of which P. aeruginosa is a species (Willey et 
al., 2017).  
 2.2.2 Biology and morphology of Pseudomonas aeruginosa 
The Phylum contains mostly chemoorganotrophs, fermentative and 
facultative anaerobic proteobacteria (Willey et al., 2017). P. aeruginosa is 
an aerobic, rod-shaped, Gram-negative, asporogenous and 




monoflagellated γ-proteobacteria (Figure 2.1a), and uses the pentose 
phosphate pathway and the Etner-Doudoroff (ED) pathway. The pentose 
phosphate pathway is an anabolic metabolic pathway that runs in parallel 
with glycolysis, where it generates NADPH, pentoses and ribosome 5-
phosphate for the synthesis of nucleotides (Willey et al., 2017). The ED 
pathway is a catabolic metabolic pathway that often occurs in Gram-
negative bacteria, some Gram-positive bacteria and archaea. This pathway 
uses an alternate series of reactions and enzymes to catabolize glucose to 
pyruvate than that of the pentose phosphate pathway. Both of these 
pathways provide the bacteria the ability to modify its’ metabolism and 
actively pump out antibiotics from within the cell and allowing it to increase 
its’ antibiotic resistance (Lambert, 2002; Livermore, 2002; Nadal Jimenez et 
al., 2012; Willey et al., 2017; Gellatly and Hancock, 2013).  
P. aeruginosa is versatile in nutrition and a rod of approximately 1-5 µm long 
and 0.5-1.0 µm wide. It may fluoresce under ultra-violet (UV) light (Figure 
2.1b) in 65% of cases but this cannot be used as identification in all cases 
(Willey et al., 2017).  
       
Figure 2. 1 a) A high-power scanning electron microscope of P. aeruginosa. 
(Tsang et al., 2003). b) P. aeruginosa fluorescence under UV light 
(Banerjee et al., 2017).  
The cell envelope of P. aeruginosa consists of three layers; the cytoplasmic 
membrane, the peptidoglycan layer and the outer membrane (Caveney et 
a) b) 




al., 2020). The outer membrane consists of phospholipids, protein and 
lipopolysaccharides (LPS). The LPS consists of heptose, 2-keto-3-
deoxyoctonic acid, hydroxy fatty acids, side chain and core 
polysaccharides. This composition contributes to the MDR and cause for 
nosocomial infections ( Caveney et al., 2020). 
P. aeruginosa is also identified by its distinctive odour of grapes or tortilla in 
vitro. It is lactose-negative and is not an active fermenter of carbohydrates 
and produces acid but no gas in glucose. Oxidase and catalase tests for P. 
aeruginosa are positive when tested ( Willey et al., 2017). 
2.2.3 Pathogenesis 
P. aeruginosa has seemingly endless ability to develop resistance to 
antibiotics since its genome has more than 50 resistance genes, which is 
assisted by mutating the chromosomal genes. P. aeruginosa has a cell wall 
that has low permeability and the pathogen acquires additional resistance 
genes from other organisms through their plasmids, transposons and 
bacteriophages. P. aeruginosa also pumps out any drugs and antiseptics 
so that it is unaffected by these, even in high concentrations by using the 
pentose phosphate pathway and the ED pathway (Lambert, 2002; 
Livermore, 2002; Nadal Jimenez et al., 2012; Gellatly and Hancock, 2013). 
The pumping out of drugs and antiseptics is made possible by the efflux 
pumps of P. aeruginosa. P. aeruginosa has four efflux pumps that are up-
regulated in clinical isolates: MexAB-OprM, MexCD-OprJ, MexEF-OprN 
and MexXY, of which MexAB-OprM is important as it provides intrinsic 
resistance to a wide spectrum of antibiotics (Rampioni et al., 2017; 
Shrestha, et al., 2020). When P. aeruginosa is exposed to a stimulus, the 
efflux pumps are activated and the stimulus is actively pumped out the cell 
while it migrates away from the stimulus in chemotactically (Lai et al., 2009; 
Rampioni et al., 2017; Caveney et al., 2020).  




2.2.4 Main types of Pseudomonas spp 
There are several types of Pseudomonas and include: P. aeruginosa, P. 
fluorescens, P. putida, P. cepacia, P. stutzeri, P. maltophilia, P. 
putrefaciens, P. mallei and P. pseudomallei (Iglewski, 1996; Boucher et al., 
2013; Wu, 2015; Willey et al., 2017; Chakhtoura et al., 2018). 
Table 2.1 summarises the areas in the environment where the different 
species can be found and what possible diseases they can cause. 




Table 2. 1 Different types of Pseudomonas spp. 
 
Organism Places found Mechanism of action Diseases caused References 
P. aeruginosa Soil, water, 
vegetation, skin, 
throats and stools 
Can pump antibiotics and 
antiseptics out the cell and can 
show gene mutation to be 
MDR 
Nosocomial infections such as 
pneumonia, urinary tract 
infections and bacteraemia. 
Outcome or complication of 
disease may be life threatening. 
Iglewski, 1996; Boucher 
et al., 2013; Wu et al., 
2015; Willey et al., 2017; 
El Chakhtoura et al., 
2018 
 
P. fluorescens Soil, water, 
vegetation, 
refrigerated milk, 
meat, eggs and 
seafood 
Degrades lipids and proteins Blood transfusion septicaemia, 
catheter related bacteraemia 
and peritonitis 
P. putida Soil and water Uses a wide variety of organic 
compounds as energy sources 
and is studied for its role in 
catabolic pathways and 
bioremediation 
Bacteraemia, pneumonia, 
septicaemia, acute cholecystitis, 
cholangitis, tonsillitis, skin and 
soft tissue infections. 
 





Table 2.1 continued         Different types of Pseudomonas spp.  
 
Organism Places found Mechanism of action Diseases caused References 
P. cepacian Soil, water and 
vegetation 
Causes soft rot in 
plants and has the 





Surgical and burn wound infections, 
bacteraemia, meningitis, pneumonia, 
peritonitis, urinary tract infections 
Iglewski, 1996; Boucher 
et al., 2013; Wu et al., 
2015; Willey et al., 2017; 
El Chakhtoura et al., 
2018 
 
P. stutzeri Soil and water Denitrifying bacterium 
that can degrade 
carbon tetrachloride 
Rarely leads to serious community or 
nosocomial acquired infections but 
endocarditis, infections of the bone, eye, 
skin or urinary tract, meningitis, 
pneumonia, arthritis, and several other 
diseases have been recorded 




Gene mutation to be 
MDR 
Pneumonia, urinary tract infections and 
bacteraemia. Infections are difficult to treat 
and associated with high morbidity and 
mortality in severely immunocompromised 
and debilitated individuals 





Table 2.1 continued         Different types of Pseudomonas spp.  
 
Organism Places found Mechanism of action Diseases caused References 





reduce iron and 
manganese 
metabolically 
Infections in severely compromised 
individuals and can cause bacteraemia 
Iglewski, 1996; 
Boucher et al., 2013; 
Wu et al., 2015; Willey 
et al., 2017; El 
Chakhtoura et al., 2018 
 
P. mallei Horses  Can be transmitted to 
humans via skin 
contact and inhalation 
Glanders 
P. pseudomallei Soil in the tropical 
and subtropical 
regions 
Infects humans and 
animals 
Melioidosis 




2.2.5   Predisposing factors of infections caused by P. aeruginosa 
Predisposing and risk factors for P. aeruginosa infections are a history of 
previous infections within the last year, which includes: if the patient was on 
mechanical ventilation or had a tracheostomy, bedridden or disabled, in an 
Intensive Care Unit (ICU), had a prolonged stay in hospital as well as any 
history of chronic pulmonary diseases such cystic fibrosis, emphysema-
interstitial lung disease, bronchiectasis and chronic bronchitis (Shi et al., 
2019). A patient who is immune compromised, of a mature age of around 
86 years and older, or new-born infants are at risk of acquiring a P. 
aeruginosa infection (Restrepo et al., 2018; Shi et al., 2019). 
Other risk factors for infection are soft tissue injuries such as burns or post-
surgery wounds; use of a urinary catheter; bacteraemia in the 
immunocompromised; diabetic foot due to diabetes and impaired 
microvascular circulation; and otitis externa such as swimmer’s ear due to 
water blockage in the ear canal (Restrepo et al., 2018). Keratitis due to 
extended contact lens wearing or from contaminated contact lens solution 
as well as hot tub rash from improperly cleaned hot tubs (Gellatly and 
Hancock, 2013) are also known risk factors. 
2.2.6 Infections caused by P. aeruginosa 
P. aeruginosa can cause infections in many areas of the body (Iglewski, 
1996). Figure 2.2a gives a brief summary of the common areas of infection 
with P. aeruginosa and Table 2.2 gives the details of each infection. P. 
aeruginosa infections can be found in the lower respiratory tract, urinary 
tract, surgical wounds, skin and blood infection (Restrepo et al., 2018; Shi 
et al., 2019). 
This pathogen, due to its many mechanisms of being resistant, proliferates 
easily and forms biofilms (Figure 2.2b), which increases its resistance to 
antiseptics and antibiotics and makes infections difficult to treat (Willey et 
al., 2017). The most dangerous infections caused by P. aeruginosa is 




malignant external otitis media, endocarditis, meningitis, pneumonia, 
endophthalmitis and septicaemia (Restrepo et al., 2018; Shi et al., 2019).. 
Most of these cases involve immunocompromised patients and/or result 
due to a prolonged stay in hospital where patients are exposed to MDR P. 
aeruginosa in ventilation tubes and catheters infection (Restrepo et al., 
2018; Shi et al., 2019). 
    
Figure 2. 2 a) Common areas of infection with Pseudomonas aeruginosa 
(Iglewski, 1996; Furaro et al., 2018). b) A three-dimensional 
reconstruction of a Pseudomonas aeruginosa biofilm. The biofilm 
was exposed to an antibacterial agent and then stained with dyes 
that distinguish living (green) from dead (red) cells. The cells on the 
surface of the biofilm have been killed, but those in the lower layers 
of the biofilm are still alive (Willey et al., 2017). 
2.2.7 Conventional treatments for infections by Pseudomonas 
aeruginosa  
Current treatment for multidrug resistant (MDR) Pseudomonas aeruginosa 
(P. aeruginosa) includes Amikacin, Cefepime, Ceftazidime, Ceftriaxone, 
Ertapenem, Imipenem, Levofloxacin and Piperacillin–tazobactam (de Breij 
et al., 2018; Pletzer et al., 2018). There is a significantly high resistance to 
Cefepime, Ceftazidime, Ceftriaxone, Levofloxacin and Piperacillin-
tazobactum (Karlowsky et al., 2017). Table 2.3 provides information on the 
different types of antibiotics that are still effective and their mechanism of 
action. 
a) b) 




Table 2. 2        Infections caused by P. aeruginosa 
 
Infections Diseases High Risk groups Treatment References 
Skin and soft 
tissue 
infections 




• Chronic leg ulcers 
• External otitis 
(swimmer’s ear) 
• Ecthyma gangrenosum 







• Intravenous catheter 






• Irrigation with a 1% acetic acid 
solution in cases of otitis media 
with topical polymyxin B, colistin, 
or fluoroquinolone for severe 
infections. 
• Debridement of necrotic tissue and 
drainage of abscesses together with 
antibiotic therapy. 
• Amputation of affected limb (in rare 
cases). 
Serra et al., 2015; Wu et 
al., 2015; Esposito, et al., 
2016; Cafasso, 2019; 
Kanji and Sexton, 2019 
Eye 
infections 
• Corneal infections 
• Blepharo-conjunctivitis 
• Endophthalmitis 
People with higher risk 
wear contact lenses, use 
contaminated contact 
lens fluid 
• Polymyxin B 
• "Varidase" (streptokinase-
streptodornase) 
Restrepo et al., 
2018; Cafasso, 
2019; Kanji and 


























• Cystic fibrosis 
• Chronic Obstructive 
Pulmonary Disease 
(COPD) 
• Pregnant women 
• Smoking 
• Patients in Intensive 




• Antibiotics ending with floxacin 
• Intravenous antibiotics 
• Inhaled antibiotics 
Restrepo et al., 2018; 
British Lung Foundation, 
2019; Cafasso, 2019; Shi 













• Antibiotics ending with floxacin 
• Intravenous antibiotics 
Gransden et al., 1995; 
Micek et al., 2005; 
Gellatly and Hancock, 
2013; Baddour et al., 
2015; 











• Septic shock 
• Blood clots 
• Neutropenia 
• Rheumatic heart 
disease 
• Heart valve 
replacement with 
prosthetic valve  
• Intravenous (IV) drug 
abuse 
• Compromised immune 
system 









Restrepo et al., 2018; 
Cafasso, 2019; Kanji and 






• Kidney failure 
• Nephrotic syndrome 
• Indwelling urinary 
catheter 
• Being female 
 
• Anti-pseudomonal penicillin 
• Cephalosporins 
Mittal et al., 2009; Serra 
et al., 2015; Wu et al., 
2015; Esposito et al., 
2016; 




Table 2.2 continued           Infections caused by P. aeruginosa 
 
 • Anasarca 
• Heart failure 
• Hypo or hypertension 
 
• Compromised immune 
system 










Lamas Ferreiro et al., 
2017; Cafasso, 2019; 






• Brain abscess 
• Spinal abscess 
 
• Infective endocarditis 
• Pneumonia 
• Urinary tract infection 
• Head injury 
• Neurosurgical 
procedures 
• Anti-pseudomonal penicillin 
• Cephalosporins 





• Intravenous antibiotics 
 
 
Restrepo et al., 2018; 
Shi et al., 2019. 













• Premature infants 
• Neutropenic cancer 
patients 
• Ceftazidime 




Bassetti et al., 2018; 
Restrepo et al., 2018; 
Shi et al., 2019 
 




Table 2. 3  List of effective antibiotics and their mechanism of action 
Name of 
antibiotic 
Type of antibiotic Mechanism of action References 
Amikacin Aminoglycoside Stops the growth of bacteria by binding to the bacterial 
30S ribosomal subunits and interferes with mRNA binding 
and tRNA acceptor sites 
Willey et al., 2017; Dou et al., 
2017; Karlowsky et al., 2017; de 
Breij et al., 2018; Pletzer et al., 
2018 
 
Cefepime Cephalosporin Interferes with bacterial wall synthesis and inhibits the 
cross-linking of peptidoglycan. It also plays a role in the 




Cephalosporin Irreversibly inhibits the enzymes for cell-wall synthesis, 
such as PBP3 (penicillin binding protein 3), by binding to 
transpeptidases. These medications are effective in cases 
where there is resistance to Gentamicin and Vancomycin 









Table 2.3 continued        List of effective antibiotics and their mechanism of action  
Ertapenem β-lactam Chemically acylating an active-site serine residue on 
bacterial PCP 
Willey et al., 2017; Dou et al., 
2017; Karlowsky et al., 2017; de 
Breij et al., 2018; Pletzer et al., 
2018 
 
Imipenem Carbapenem Inhibits bacterial cell-wall synthesis by binding to PCP 
Piperacillin–
tazobactam 
Dual antibiotic of 
penicillin and β-
lactamase inhibitor 
Tazobactam inhibits β-lactamase and prevents the 
destruction of piperacillin, which inhibits bacterial cell-
wall synthesis by binding to PCP 
Levofloxacin quinolone Inhibits the bacterial DNA gyrase and topoisomerase II 




Due to MDR of this organism, there have been some studies on the use of 
synthetic peptides which are used in conjunction with the antibiotics 
Ciprofloxacin, Meropenem, Erythromycin, Gentamicin and Vancomycin (de 
Breij et al., 2018; Pletzer et al., 2018). These studies have found that the 
combination treatment shows synergistic effects to reduce and clear 
bacterial isolates (de Breij et al., 2018). The in vitro data collected suggests 
that the mechanism of peptide action in vivo, allows for the enhancement of 
antibiotic penetration and does not induce bacterial resistance. It may assist 
in the treatment of these pathogens that are resistant to conventional 
antibiotics (de Breij et al., 2018; Pletzer et al., 2018). Table 2.4 shows the 
resistance of P. aeruginosa to common antibiotics (Dou et al., 2017). 
Table 2. 4 Annually detected resistance of P. aeruginosa to common anti-
Gram-negative antibiotics from 2007–2014. 
 Year 
 
2007 2008 2009 2010 2011 2012 2013 2014 
Antibiotic tested Annual percentage of P. aeruginosa to antibiotic in % 
Amikacin 42.3 22.5 45.7 61.8 73.3 88.4 79.7 85.0 
Cefoperazone-sulbactam 23.1 40.0 47.8 68.8 73.3 87.1 78.3 82.5 
Ceftazidime 26.9 22.5 60.9 20.8 32.6 14.3 15.9 46.2 
Ciprofloxacin 53.8 52.5 58.7 14.3 18.6 17.1 48.5 71.2 
Imipenem 42.3 45.0 58.7 74.0 77.9 87.0 81.2 86.2 
Meropenem 38.5 57.5 54.3 74.0 72.9 88.4 81.2 87.3 
The annual percentage (%) of P. aeruginosa strains resistant to specific 
antibiotics was measured by the Kirby–Bauer disk diffusion method (Dou et al., 
2017). 
2.3 P. aeruginosa antimicrobial resistance to antibiotics 
Due to the overuse of antibiotics, antiseptics and patients’ non-compliance, 
many pathogens are now MDR. The additional effects of poor infection 
control in healthcare settings, poor hygiene and sanitation as well as the 




use of antibacterial deodorants, mouthwashes, soaps have led to weaker 
immune systems as the body is no longer exposed to microbes to build a 
resistance to them. The presence of antibacterial agents in cutting boards 
and baby toys has led to an increase in drug-resistant bacteria as bacteria 
adapt to survive in different environments (Breidenstein et al., 2011). 
Due to the bacteria’s resistance to conventional medication, there is a need 
to look at new and alternative methods in the treatment and control of such 
organisms (Pletzer et al., 2018; Pachori et al., 2019).  
2.3.1  Novel approaches to resistance  
There have been a few studies and a renewed interest in finding new 
medications in the treatment of MDR infections, as discussed below. Many 
medications used today had their origin from plants where the biologically 
active constituents were isolated from plants that have been used in 
traditional and complementary medicine (Namita and Mukesh, 2012).  
Traditional medicine as defined by the WHO (2021) refers to the knowledge, 
skills and practises grounded on the theories, beliefs, and experiences 
indigenous to different cultures, used in the maintenance of health and 
prevention, diagnosis, improvement or treatment of physical and mental 
illness. The terms “complementary medicine” or “alternative medicine” refer 
to a broad set of health care practices that are not part of that country’s own 
tradition or conventional medicine and are not fully integrated into the 
dominant health-care system. In contrast, by definition, “herbal medicines” 
include herbs, herbal materials, herbal preparations and finished herbal 
products, that contain as active ingredients parts of plants, or other plant 
materials, or combinations thereof. 
The antimicrobial properties of certain complementary medicines, herbs 
and plants are reported on in many different places in the world but without 
the intense side-effects associated with some conventional medications in 
use. Homeopathy and phytotherapy, as further explained below, are   




complementary medicine modalities and natural healing systems that also 
make use of the whole plant or herb uniquely prepared (Chauhan and 
Gupta, 2012; Biswas et al., 2013; Ozioma and Chinwe, 2019).  
2.4 Homeopathy 
2.4.1 History of Homeopathy 
Homeopathy is a holistic form of complementary medicine that aims at 
treating the whole person instead of the physical symptoms. The word 
“Homeopathy” (“homoios” means similar and “pathos” means suffering) was 
coined by Doctor Samuel Hahnemann. Hippocrates developed the principle 
of “like cures like”; this law of similar forms the foundation of Homeopathy 
(Chauhan and Gupta, 2012). 
2.4.2 The Law of Similar 
“The law of similar” is a therapeutic method based on the principle that 
illness can be treated by giving a small dose of a substance to a sick 
individual, that if given to a healthy person in a large dose will cause 
symptoms like the illness being treated (Hahnemann, 1922). Modern 
medicine vaccines and allergy desensitization therapies operate in this 
same principle (Chauhan and Gupta, 2012). 
2.4.3 Infinitesimal doses 
Dr Samuel Hahnemann used the infinitesimal dose to reduce the side 
effects of the original substance. Through the pharmacological process 
known as “potentization”, Hahnemann could eliminate the potential outward 
effects of the medicine while preserving its healing properties (Hahnemann, 
1922). The method of extraction differs whether the ingredient is soluble in 
the case of plant material or insoluble in the case of minerals (Hahnemann, 
1922; Chauhan and Gupta, 2012). 





Potentization is known as a serial dilution plus agitation. Homeopathic 
medicines begin with a mother tincture in the case of plant materials or 
triturations in the case of insoluble preparations. The German Homeopathic 
Pharmacopoeia is often used by manufacturing companies; it explains how 
to prepare different materials used in Homeopathy such as plant materials, 
minerals and animal by-products. In the German Homeopathic 
Pharmacopeia, preparation of the plant materials begins with the harvesting 
of the fresh plant. The plant is then finely chopped and soaked in alcohol 
and water to extract the active component and filtration. This process is 
known as “maceration”. A mother tincture is the result of the process of 
maceration. The mother tincture has high bio-energetic value (Malik, 2011). 
 
The liquid extracted during the process of maceration is made more potent 
in a step-by-step process that needs more alcohol so that the resulting 
product is 1/10 of the starting material. The liquid is then shaken vigorously 
in a process known as succession producing a 1D potency. A 2D potency 
is made by taking one part of 1D and then adding it to nine parts of alcohol 
and then it is succussed. This process is repeated for successive potencies. 
The effective surface area of the healing substance is said to be increased 
by this method of dilution and molecular agitation, hence there is an 
increase in the self-healing power of the organism (Hahnemann, 1922; 
Chauhan and Gupta, 2012). 
 
Insoluble substances such as minerals and animal by-products are 
prepared by using one part of the original substance and mixing it with nine 
parts of an inert medium usually lactose. This mixture is then grounded by 
a process of trituration. This first triturate results in a 1D (Caminsky and 
Hohl, 2018).  
 
To make further potencies, 1 part of 1D is taken and triturated with 9 parts 
lactose for the decimal potency scale. For a 1C triturate, the ratio of 




insoluble material to lactose is 1 part insoluble substance to 99 parts 
lactose. (Chauhan and Gupta, 2012; Caminsky and Hohl, 2018).  
2.5 Psidium guajava L. 
Psidium guajava L. (P. guajava L.) also commonly known as guava, is a 
small tropical tree that is grown commercially for its fruit. It is referred to as 
the “poor man’s apple” due to its high nutritional content of ascorbic acid, 
beta carotene, essential vitamins and minerals. The fruit is consumed fresh 
or used to make preserves, jams and beverages. P. guajava L. belongs to 
the Myrtaceae family which has around 133 genera and 3800 species. The 
leaves, roots and bark of Psidium guajava L. tree have been used for a long 
time in traditional herbal medicine (Joseph and Priya, 2011) and have 
antimicrobial activity on both Gram-negative and Gram-positive bacteria 
(Abubakar, 2009; Joseph and Priya, 2011; Birdi et al., 2017). Figure 2.3a 
shows the Psidium guajava L. tree and figure 2.3b, the leaves and fruit.  
 
Figure 2. 3  a) Psidium guajava L. tree (Fern, 2019). b) Psidium guajava L. 
leaves and fruit (Fern, 2019). 
Phytotherapy is the science-based medical practice of using and 
administering medicinal herbs and plants to treat patients. Phytotherapy has 
shown that various plant-based medications have antimicrobial action 
without side-effects and many herbal preparations have been used in the 
treatment of various illnesses (Ozioma and Chinwe, 2019). Psidium guajava 
a) b) 




L. has been used in phytotherapy to treat and manage many diseases. 
Different parts of the plant have been used in traditional medicine to treat 
colic, cataracts, hyperlipidaemia, cardiovascular disease, pain, malaria, 
gastroenteritis, diarrhoea, wounds, ulcers, coughs, sore throats, toothache, 
dysentery, vomiting, gingivitis, diabetes, hypertension, cancer and obesity, 
skin infections, wounds, ulcers and boils (Biswas et al., 2013). 
The parts used of P. guajava L. medicinally are the leaves, leaf buds, 
flowers, seed, fruit, pulp and peels. The leaves contain flavonoids such as 
quercetin, avicularin and guaijaverin as well as tannin, apigenin, and other 
polyphenols, triterpenes, saponins, lectins, carotenoids, vitamin C, and fatty 
acids. The essential oil of P. guajava L. contains cineol, limonene, eugenol, 
caryophyllene, pinene, myrcene, cinnamic acid and hexenoic acid (Anand 
et al., 2016). 
There are many techniques used for the medicinal plant extraction which 
includes maceration, infusion, digestion, decoction, percolation, aqueous-
alcoholic extraction by fermentation, ultrasound extraction, supercritical fluid 
extraction, Soxhlet extraction, phytotonic extraction and microwave-
assisted extraction (Gonçalves et al., 2008; Biswas et al., 2013; Bezerra et 
al., 2018). The quality of the extraction is dependent on the origin of the 
plant material, the variation of the extraction techniques, the time and 
temperature of the extraction, solvent concentration and polarity, and 
secondary metabolite composition of the extract (Akoma and Olawepo, 
2002). 
2.5.1 Psidium guajava L. herbal extract 
Research studies have been done to provide an acceptable monograph for 
Psidium guajava L. leaf extract. The extracts were measured using ultra-
high performance liquid chromatography coupled with electrospray 
ionization-quadrupole-time of flight-mass spectrometry (UPLC-ESI-QTOF-
MS) and showed the active ingredients found in Psidium guajava L. leaf 
extracts. In Bezerra et al., (2018), the chromatograph of Flavonoid Fraction 




of Dried Leaves of Psidium guajava L. (FFDLPG) and the chromatograph 
of Tannic Fraction of Dried Leaves of Psidium guajava L. (TFDLPG) was 
done. From the results of the chromatographs of FFDLPG and TFDLPG, 11 
compounds were identified including flavonoids, tannins, triterpines, lectins, 
quercetins, leucocyanidins, sequiterpenes and an acetophenone, which 
confirms previous research and hypotheses on the contents of Psidium 
guajava L. leaves (Abubakar, 2009; Barbalho et al., 2012).  
The method of herbal extract manufacturing of Psidium guajava L. depends 
on the manufacturer as well as the level of active ingredients needed per 
millilitre. Herbal extracts are generally prepared in a 1 part dried material to 
5 parts solvent ratio or a 1 part dried material to 10 parts solvent dependant 
on the plant and its constituents as well as the type of starting material. The 
method of extraction may also change if it is dried herb or fresh (Caminsky 
and Hohl, 2018). P. guajava L. Herbal Extract was prepared according to 
the British Pharmacopoeia with 1 part dried material to 10 parts solvent for 
this study (British Pharmacopoeia, 2018; Perry, 2019). 
2.5.2 Homeopathic symptom picture Psidium guajava L. 
There is no homeopathic symptom picture as no research exists on the use 
of Psidium guajava L. prepared homeopathically. This is the first time that a 
homeopathic remedy is being made of Psidium guajava L. 
Homeopathic tinctures retain all of the active compounds but through the 
process of preparing the tincture and potencies, the medication is purified 
and the active ingredient ratios are also diluted. A pure but less 
concentrated active compound in the medication would mean that the 
medication is more cost effective without the risk of any side-effects of 
people to the medication (Hahnemann, 1922; Chauhan and Gupta, 2012). 




2.5.3 Psidium guajava L. homeopathic mother tincture 
The mother tincture is manufactured according the German Pharmacopoeia 
method 4a. These tinctures are made according to a maceration or 
percolation method as described in the European Pharmacopoeia. One part 
of herb to 10 parts of ethanol in a suitable concentration is used. The ethanol 
is combined with the filtrate and the mixture is left for minimum amount of 
days in a room with a temperature not exceeding 20°C. The mixture is then 
filtered to remove particulates and herb from the fluid. The mother tincture 
(Ø) is equal to a D1 (first decimal dilution) potency (Caminsky and Hohl, 
2018; Ferguson, 2019). 
2.5.4 Psidium guajava L. 3cH potency 
The potencies are made from the mother tincture and through sequential 
dilutions and succussions up to 3cH potency. The method followed is HAB 
5A (Ferguson, 2019).  
The 1cH (first centesimal) potency is made from 10 parts Ø (=D1) and 90 
parts of ethanol of the same percentage. The remedy is succussed 100 
times to make up 1cH potency (Caminsky and Hohl, 2018). 
The 2cH potency is made from 1 part of 1cH and 99 parts of 43% ethanol 
and succussed 100 times. The 3cH potency is made following the same 
method of from 1 part of 1cH and 99 parts of 43% ethanol and succussed 
100 times (Caminsky and Hohl, 2018). 
2.5.5 Psidium guajava L. herbal extract effect on bacteria 
Aqueous and organic extracts of guava leaves have demonstrated to have 
antibacterial activity due its inhibitory effect against antibiotic-resistant 
clinical isolates of Staphylococcus aureus strains (Anas et al., 2008; Milyani, 
2012). Though the same diffusion method was used there were differences 
in their inhibition zones due to the extraction method as indicated by a 
methanol extract. It showed antibacterial activity and prevented the growth 




of different strains of different bacteria like Staphylococcus aureus, 
Escherichia coli, Pseudomonas aeruginosa, Proteus spp., and Shigella spp. 
9 (Chah et al., 2006). The different extracts of the leaves like aqueous, 
acetone–water, methanolic, spray-dried extracts and essential oil, showed 
possible inhibitory action against Gram-positive and Gram-negative 
bacteria and fungi (Nair and Chanda, 2007; Dhiman et al., 2011; Nisha et 
al., 2011; de Araújo et al., 2014; Fernandes et al., 2014). Gram-positive 
bacteria showed a greater inhibition zone and minimum inhibitory 
concentration (MIC) than Gram-negative bacteria. Anti-fungal activity, 
though, was less inhibited than for bacteria except for Candida krusei and 
Candida glabrata, which showed greater inhibition zones and MIC than 
Gram-negative bacteria (Nair and Chanda, 2007; Dhiman et al., 2011; 
Fernandes et al., 2014). Bezerra et al., (2018) evaluated the effect of guava 
leaves on different bacterial strains and concluded that synergistic action 
between leaves and a variety of antibiotics boosted the anti-bacterial 
activity. Metwally et al., (2011) compared the antimicrobial activity against 
some bacteria and fungi with five flavonoids that were isolated from guava 
leaves and found that the effect was related to the concentration of tannin 
in the leaves as well as the concentration of gallic acid and catechin.  
Guava leaves have also been used traditionally for the treatment of 
diarrhoea caused by enteric pathogens, and it has shown significant 
inhibitory activity against Vibrio cholerae and V. parahemolyticus, 
Aeromonas hydrophila, Escherichia coli, Shigella spp. and Salmonella spp. 
(Birdi et al., 2010; Chanu et al., 2011; Ngene et al., 2019). There was also 
a reduction in V. cholera invasion and attachment to human laryngeal 
epithelial cells, as well as a decrease in the production of E. coli and cholera 
toxins (Birdi et al., 2010).  
Guava leaf tea has also helped to control the growth of influenza viruses 
and includes the oseltamivir-resistant strains, by preventing the virus to 
enter into host cells due to the presence of flavonoids (Sriwilaijaroen et al., 
2012). 




Through several studies and as more research is conducted in a time where 
MDR bacteria poses a threat to humankind, further study and investigation 
of Psidium guajava L. leaf extract might demonstrate effective use as a new 
pharmaceutical application in a wide area of application (Biswas et al., 
2013). 
  






3.1 Experimental design 
This quantitative in vitro study on the potential antimicrobial effects of P. 
guajava L. herbal and mother tinctures on Pseudomonas aeruginosa strains 
was conducted at the University of Johannesburg Water and Health 
Research Centre (WHRC), Doornfontein campus. Experiments were 
performed under the supervision of a qualified laboratory technician and 
after necessary permission was granted (Appendix C). 
3.2 Antimicrobial agents 
P. guajava L. herbal tincture was obtained from Phyto-Force Herbal 
Laboratories. It was prepared according to the British Pharmacopoeia by 
macerating the herb in ethanol (96,2% rectified spirits) and purified water 
(50% ethanol and 50% purified water) for a period of 14 days (British 
Pharmacopoeia, 2018). Following this the liquid was strained and subjected 
to a series of microbiological testing and pH testing (Perry, 2019).   
P. guajava L. mother tincture was obtained from W. Last cc. W. Last cc is 
homeopathic tincture manufacturer. The P. guajava L. mother tincture was 
prepared according to the German Homeopathic Pharmacopoeia (GHP) 
HAB 4a with 62% ethanol. The tincture was prepared from the dried herb  
in a 1:10 ratio. P. guajava L. 3cH potency was prepared from the P. guajava 
L. mother tincture according to the German Homeopathic Pharmacopoeia 
(GHP) HAB 5a with 45% ethanol (Ferguson, 2019). 
3.3 Stock cultures 
A Pseudomonas aeruginosa reference strain (ATCC® strain 27853) was 
purchased from Media Mark and used as control strain for all experiments.  




Environmental strains isolated and characterised in previous studies were 
obtained from the WHRC and are listed in Table 3.1 together with their 
antibiotic resistance to various antibiotics tested. 
The strains were stored as glycerol stocks at -80°C at the WHRC and grown 
overnight (24 hours) on Mueller-Hinton agar plates or in Mueller-Hinton 
broth at 35°C, when needed. 
3.4  McFarland standard 
To ensure consistent results, bacterial suspensions were adjusted to 0.5 
McFarland standard for all experiments using the bioMérieux densiCHEK. 
This was achieved by using an overnight culture from agar plates (as in the 
Kirby-Bauer Disk diffusion method) or from liquid cultures (as with the broth 
dilution cultures in Minimum Inhibitory Concentrations). 
Briefly, a strain was grown on a Mueller-Hinton agar plate for 16-18 hours 
at 35°C. A sterile cotton swab was used to pick a colony from the plate and 
added to 0.9% saline solution and adjusted as needed to achieve a bacterial 
suspension of 0.5 McFarland. Strains grown in a liquid medium of Mueller-
Hinton broth overnight were adjusted with sterile liquid media, so that their 
turbidity of bacterial suspension was 0.5 McFarland. 
3.5 Media preparation 
Mueller Hinton agar and broth were prepared as described by the 
manufacturer. All media prepared were sterilized by autoclaving at 121°C 
and 15 Pound per Square Inch (P.S.I) for 1 hour and placed in a water bath 
at 40-50°C. When the Mueller Hinton agar cooled to about 50°C it was 
poured into sterile petri dishes, allowed to cool and stored at 4°C until used.




Table 3. 1 Pseudomonas aeruginosa isolates obtained from the WHRC and their resistance to antibiotics with their mechanism of action. 


















































































































   PS1 Hospital PAT13 GN Ps. aeruginosa R R R R R I S S S S R S 
PS2 Hospital PAT17 GN Ps. aeruginosa R R R R R I S S S S R S 
PS3 Hospital PAT18 GN Ps. aeruginosa R R R R R I S S S S R S 
PS4 Hospital PAT20 GN Ps. aeruginosa R R R R R R S S S S R I 
PS5 Hospital PAT22 GN Ps. aeruginosa R R R R R R S S S S R I 
PS6 Hospital PAT23 GN Ps. aeruginosa R R R R R R S S S S R R 
PS7 Hospital B5(17) GN Ps. aeruginosa R R R R S S R R R R R S 
PS8 Hospital B5(201) GN Ps. aeruginosa R R R R S S R R R R R S 
PS9 Hospital B6(36)10 GN Ps. aeruginosa R R R R R R R R R S R S 
PS10 Hospital PET27 GN Ps. aeruginosa R R R R R R R R R S R S 
PS11 Hospital B6(28) GN Ps. aeruginosa R R R R S I R R R S R S 
PS12 Hospital B4(17) GN Ps. aeruginosa R R R R R I S S S S R I 
PS13 Hospital P5 GN Ps. aeruginosa R R R R S S S S S S R S 
PS14 Hospital P29 GN Ps. aeruginosa R R R R R R S S S S R S 
PS15 Hospital B6(53) GN Ps. aeruginosa R R R R S S R R R R R S 




Table 3.1 continued Pseudomonas aeruginosa isolates obtained from the WHRC and their resistance to antibiotics with their 


















































































































  PS16 Hospital B6(38)16 GN Ps. aeruginosa R R R R S S S S S S R S 
PS17 Hospital PAT10 GN Ps. aeruginosa R R R R R I S S S S R I 
PS18 Hospital PAT1 GN Ps. aeruginosa R R R R R I S S S S R S 
PS19 Hospital PAT25 GN Ps. aeruginosa R R R R R I R R R S R S 
PS20 Control 
P. aeruginosa (ATCC® 
strain 27853) GN Ps. aeruginosa 
R R R R R I R R R R R I 
PS21 Hospital PAT2 GN Ps. aeruginosa R R R R S S S S S S R S 
PS22 Hospital PAT6 GN Ps. aeruginosa R R R R S S S S S S R S 
PS23 Hospital PAT7 GN Ps. aeruginosa R R R R S S S S S S R S 
PS24 Hospital PAT8 GN Ps. aeruginosa R R R R S S S S S S R S 
PS25 Hospital PAT11 GN Ps. aeruginosa R R R R S S S S S S R S 
PS26 Hospital PAT14 GN Ps. aeruginosa R R R R S S S S S S R S 
 
      




3.6 Kirby-Bauer disk diffusion method 
Kirby-Bauer Disk Diffusion method is recommended by the Clinical 
Laboratory Standards Institute (Hudzicki, 2017) and the standardised 
protocol was used for the experiments. To create P. aeruginosa bacterial 
lawns, a bacterial suspension equal to 0.5 McFarland standard as described 
earlier (section 3.4) was utilized. A hundred microliters of the bacterial 
suspension was evenly spread onto a Mueller Hinton agar plate to form a 
bacterial lawn, and then allowed to dry for 3 to 5 minutes. All antibiotic disks 
and sterile disks were evenly placed on the surface of the plate using flame 
sterilized forceps. After aseptically placing the disks on the plate, the sterile 
disks were impregnated with 10µl of Psidium guajava L. HE, Psidium 
guajava L. Ø, Psidium guajava L. 3cH, as well as 2 negative controls of 62% 
and 50% ethanol and a positive control, which was the antibiotic, 
Streptomycin 300 mcg.  
Each plate was numbered before incubation using a template for the 
placement of the sterile disks to allow identification and monitoring of the 
progress displayed by each plate (Figure 3.1). The plates were inverted and 
incubated at 35°C for 16-18 hours.  
 
Figure 3. 1 Template used for the placement of the sterile disks on the agar 
before inoculation of the disks with solvent. 
Following incubation, the plates were examined for a zone of inhibition of 
bacterial growth and the zone measured in millimetres around the 




impregnated disks by means of a ruler. The procedure was performed in 
triplicate (repeatability) on three independent days (reproducibility) to 
ensure reliable results. Appropriate controls (Table 3.2) were included in the 
experiments to test the reliability of the methods. Figure 3.2 shows an 
example of Kirby-Bauer disk diffusion susceptibility test with the relevant 
controls and compounds labelled accordingly.  
Table 3. 2 Controls used with the Kirby-Bauer disk diffusion susceptibility and 
Minimum Inhibitory Concentration tests. 
Control Description 
Solvents 62% and 50% ethanol to test if the solvents could contribute 
to the inhibition of bacterial growth. 
Antibiotic Included as method control to show the inhibition (positive) 
of bacterial growth. Streptomycin HLS 300 mcg was used. 
 
Figure 3. 2 Mueller-Hinton plate showing the Kirby-Bauer disk diffusion 
susceptibility test with P. aeruginosa bacterial lawn tested with P. 
guajava L. mother tincture (1), P. guajava L. 3cH (2), P. guajava 
herbal extract (3), 62% ethanol solvent used to make the mother 
tincture and 3cH (4), 50% ethanol solvent used to make the herbal 









3.7 Minimum Inhibitory Concentration method (MIC) 
The Minimum Inhibitory Concentration (MIC) is the lowest concentration of 
the compound to inhibit growth and was tested by a serial dilution method 
in 24 well plates. The 24 well plates were prepared as shown in Figure 3.3. 
All wells were filled with 1000µl Mueller Hinton broth. One thousand 
microlitres of either test compound or controls (see above) were added to 
the first well in each row. The compounds were serially diluted in the next 
well by transferring 1000 µl from the first well into that well, mixing properly, 
and by transferring 1000 µl of that well into the next well. This was continued 
to the last well (3rd well) and the last 1000µl removed discarded. Following 
this, 1000µl of the required bacterial suspension was added to each of the 
wells, excluding the media control wells. The plates were closed and 
incubated for 24 hours at 35°C in a shaking incubator at 50 rpm. Following 
incubation, 500µl of 0,04% Iodonitrotetrazolium chloride (INT) was added to 
each well and incubated for 30 minutes at 35°C. The development of a 
bright pink or dark pink colour indicated bacterial growth, i.e. no bacterial 
inhibition. All appropriate controls, media only (blank control) and media with 
bacteria only (positive control), were included on each day to ensure the 
reliability and trustworthiness of the results. 
 
Figure 3. 3 24 well plate showing the MIC of compounds tested by the serial 
dilution method 
Media control 
Media + bacteria 
+ alcohol controls 
Media + bacteria 
+ antibiotic 
Media + bacteria 
Media + 
bacteria + test 
compounds 




3.8 Minimum Bactericidal Concentration (MBC) 
The Minimum Bactericidal Concentration (MBC) is the lowest concentration 
of an antibacterial compound required to kill a specific bacterium. It is 
determined by plating samples from the wells of the MIC onto Mueller-
Hinton agar plates. This was done by plating  a loopful of the well contents 
onto the plate as shown in Figure 3.4 and incubating for 24 hours at 35°C. 
If the bacteria was only inhibited, bacterial growth will resume once the 
tincture is “removed” once it is plated out onto agar plates. No growth 
indicates that the antimicrobial agent was bactericidal, killing the bacterial 
cells (Chikezie, 2017). Figure 3.4 shows examples of bactericidal and 
bacteriostatic results with MBC. 
 
Figure 3. 4 Figures of the plates from MBC showing areas of growth 
(bacteriostatic) and areas of non-growth (bactericidal). 
3.9 Agar Overlay Disk Diffusion Method 
The Agar Overlay Disk Diffusion method was an alternative method 
performed to determine if there was a change in the way P. aeruginosa 
reacted to the tinctures if the method of Disk Diffusion was changed from 
the Kirby-Bauer Disk Diffusion method to the Agar Overlay Disk Diffusion 
method. The agar overlay method is a “swap around” of the typical disk 
diffusion method by applying the bacterial strains on top of the disk as a soft 









applied over the disks and plate. The agar is autoclaved and then cooled to 
45°C in a water bath before use. One millilitre of each bacterial suspension 
(equal to 0.5 McFarland standard) was added to 4mL of the soft agar and 
mixed before added on top of the Mueller-Hinton plates that contained the 
different disks as described in section 3.6.  
Each plate was numbered before incubation using a template for the 
placement of the sterile disks to allow identification and monitoring of the 
progress displayed by each plate as in Figure 3.1. All antibiotic disks and 
sterile disks were evenly placed on the surface of the plate using flame 
sterilized forceps. The sterile disks were impregnated with 20 µl of Psidium 
guajava L. HE, Psidium guajava L. Ø, Psidium guajava L. 3cH as well as 
relevant controls. 5mL soft bacterial agar was placed over the disks and 
allowed to solidify. Five strains were selected from the Kirby-Bauer Disk 
diffusion method experiments that showed double rings in the inhibition 
zones. The plates were inverted and incubated at 35°C for 16-18 hours.  
Following incubation, the plates were examined for a zone of inhibition of 
bacterial growth and the zone measured in millimetres around the 
impregnated disks by means of a ruler. The results were recorded for 
comparison to the corresponding strain from the Kirby-Bauer Disk Diffusion 
method. The solvents used were the same as in Table 3.1 though the 
antibiotic used was Piperacillin/Tazobactam. It has been already 
established that P. aeruginosa is inhibited by Streptomycin 300mcg in Kirby-
Bauer Disk Diffusion method, MIC and MBC. Piperacillin/Tazobactam is one 
of the main therapies used in the medical field and studies indicate that it is 
highly effective and therefore this antibiotic was used instead in this part of 
the study (Lodise et al., 2007; Sader et al., 2018). Figure 3.5 shows an 
example of Kirby-Bauer disk diffusion susceptibility test with the relevant 
controls and compounds labelled accordingly.  





Figure 3. 5 Mueller-Hinton plate showing the Agar Overlay Disk Diffusion 
method where P. aeruginosa is in the overlay agar placed over the 
disks instead of as a lawn that the disks are placed onto. The disks 
were impregnated with P. guajava L. mother tincture (1), P. guajava 
L. 3cH (2), P. guajava herbal extract (3), 62% ethanol solvent used 
to make the mother tincture and 3cH (4), 50% ethanol solvent used 
to make the herbal extract (5) and antibiotic control 
Piperacillin/Tazobactam (6). 
3.10 Erlenmeyer Flask Method 
Testing the inhibition of bacterial growth was done using Erlenmeyer Flasks 
and was done as an additional test for the MIC tests. The reason for the test 
was to determine if the tinctures would be more effective if the bacterial cells 
were forced in to suspension in a shaking incubator to prevent the formation 
of the typical biofilm observed. The same five strains that were selected for 
the Agar Overlay Disk Diffusion method were selected again.  
The total amount of fluid that was added to the Erlenmeyer flasks (50ml 
flask) was not more than 10% of the total volume of the Erlenmeyer flask. 
The Mueller-Hinton broth, bacterial suspension and tincture were kept in the 









Six flasks were used per strain, 1 flask each for P. guajava L. mother 
tincture, P. guajava L. 3cH, P. guajava herbal extract, 62% ethanol solvent 
used to make the mother tincture and 3cH, 50% ethanol solvent used to 
make the herbal extract and antibiotic control Piperacillin/Tazobactam. An 
additional flask was used as a media control. To each of the six Erlenmeyer 
flasks, 1.6mL Mueller-Hinton broth was added, 1.6mL of the corresponding 
solvent or alcohol or antibiotic and 1.6mL bacterial suspension equal to 0.5 
McFarland standard. The additional flask had 5mL Mueller-Hinton broth. 
The Erlenmeyer flasks were closed, labelled and placed in a shaking 
incubator at 35°C for 16-18 hours.  
After incubation, 500µl of Iodonitrotetrazolium chloride (INT) was added to 
each Erlenmeyer flask and incubated for 30 minutes at 35°C. The 
development of a bright pink or dark pink colour indicated bacterial growth, 
i.e. no bacterial inhibition. Figure 3.6 a) and b) shows an example of the 
Erlenmeyer flask results. The Erlenmeyer flask contents were plated out 
onto grids to double check for MBC. Figure 3.7 shows the template used for 
the grids. 
 
Figure 3. 6 a) a photo from the top of the Erlenmeyer flask to view the contents 
and see if there is a biofilm b) a photo from the side of the Erlenmeyer 
flask. 
a) b) 





Figure 3. 7 Template used for the plating out of the Erlenmeyer Flasks for grids 
to determine MBC. 
3.11 Data collection 
The zones of inhibition for each disk on all the plates were measured and 
the results were recorded in millimetres (mm). Figure 3.8 shows how the 
zones of inhibition were measured. The zones are read at the point of 
complete inhibition as seen by the naked eye. The plate should be at least 
30cm from the eye. 
 
Figure 3. 8   Measurement of zone of inhibition (Hudzicki, 2009). 
The MIC was determined as the first well where the Iodonitrotetrazolium 
chloride (INT) dye was metabolized to form a pink to purple colour showing 
Measured 
in mm 




viable cell. If the solvent showed bacterial growth inhibition (no colour in the 
wells), the number of wells was deducted from the test compound results to 
reflect the actual impact of the compound alone. 
3.12 Data analysis 
Zone of inhibition for the Disk Diffusion test is presented in Figure 4.3 and 
4.4 as well as in table format in Appendix F which shows the average, 
minimum and maximum measurements obtained. 
Since the extracts contains several active compounds and the exact 
concentration of each compound is not known, the data is presented as the 
last dilution that showed inhibition of bacterial growth in MIC. The wells that 
showed no growth (low colour or no colour from INT) were then plated out 
again onto Mueller-Hinton agar and incubated for 16-18 hours at 35°C to 
determine if the tinctures were bactericidal or bacteriostatic. The results are 
represented in table format. 
3.13 Ethical considerations 
The project was approved by the Higher Degrees Committee (HDC-01-36-
2019) and Research Ethics Committee (REC-01-46-2019) of the University 
of Johannesburg (APPENDIX A and B). There were no direct ethical 
considerations relevant to this study. The tests were conducted in a 
controlled laboratory environment. Supervision of this study and experiment 
was conducted by a board-certified laboratory technician from the Water 
and Health Research Centre, who is qualified in doing these experiments. 
The researcher was appropriately trained to conduct the experiment and 
ensured prevention of contamination or exposure to the bacterial strains (P. 
aeruginosa). 
All equipment was appropriately cleaned and sterilized before each use to 
avoid contamination and compromised results. All safety protocols were 
adhered to, to ensure laboratory safety, safe removal and disposal of 




bacterial organisms, tinctures, herbal extracts and equipment. Protective 
clothing such as gloves, safety glasses and laboratory coats were worn at 
all times to maintain and ensure safety of the researchers involved. All 
efforts were made to minimize any risks of contamination or exposure to 
bacterial strains, if exposure did occur, prompt adherence to laboratory 
protocols would have been conducted and disposal of bacterial strains 











This chapter will report on the results obtained when testing the reference 
and 25 environmental Pseudomonas aeruginosa strains against the P. 
guajava Ø, P. guajava 3cH potency and P. guajava L. HE. The sections to 
follow will report the results for the experiments outlined in sections 3.6 – 
3.10 in the previous chapter.  
4.1 Kirby-Bauer Disk Diffusion 
The first test was to screen if the P. guajava Ø, P. guajava 3cH potency and 
P. guajava L. HE had any inhibitory activity on the growth of the P. 
aeruginosa strains tested. Figure 4.1 shows an example of one of the plates 
showing zones of inhibition which can be seen around the paper disk. The 
photos of all the other plates can be found in Appendix D and a detailed 
breakdown of the measurements per strain can be found in Appendix E. 
 
Figure 4. 1 Photo of the agar plate showing the P. aeruginosa inhibition obtained 
with 1) P. guajava Ø in 62% EtOH, 2) P. guajava 3cH potency in 45% 
EtOH, 3) P. guajava L. HE in 50% EtOH, 4) 62% EtOH, 5) 50% EtOH, 
6) HLS 300. 




The plate in figure 4.2 was chosen to illustrate the “double growth ring” 
present around the disks in the zone of inhibition of disks 1, 2, 4 and 5. Many 
of the Kirby-Bauer plates showed this unusual pattern of growth in the 
presence of the tinctures and was the reason that the agar overlay tests 
was performed as described later. This double ring growth phenomenon 
(figure 4.2) was observed also reported by Rampioni et al. (2017) and was 
reported to be due to efflux pumps of P. aeruginosa, which will be discussed 
in more detail in Chapter 5. The antibiotic control created a normal clear 
zone of inhibition.  
 
Figure 4. 2 Enlarging of the P. guajava Ø (in 62% EtOH) section shown in 
Figure 4.1 to show the zone of inhibition as well as the proposed 
two growth zones observed. 
Figure 4.3 is a graphical representation of the results obtained for the 78 
tests which included the tinctures, alcohol controls and antibiotics. The 
averages of each test is indicated in mm above the chart per testing agent. 
From this graph it can be seen that the antibiotic control worked well in 
comparison to the tinctures. Streptomycin HLS 300 mcg had an average 
measurement of 25.4 mm ranging between 10-30 mm and showed 
inhibition in all strains. This was surprising as P. aeruginosa is resistant to 
Streptomycin 10 mcg according to CLSI (Clinical and Laboratory Standards 
Institute) (Patel, 2016). The inhibition experienced could be due to the 
higher dosage of the Streptomycin discs used.  






Figure 4. 3 Graphical representation of the detailed results in Appendix E. The 
average measurements for each test are indicated in the blocks 
above the chart and are in mm.   
Figure 4.4 is a graphical representation of the results presented in figure 4.3 
but without the antibiotic control resulting in a better spread of the data 
obtained and it can be seen that there are outliers to the tests.  
The P. guajava Ø had an average measurement of 6.41 mm with a range 
of 6-11 mm, P. guajava 3cH potency had an average measurement of 6.31 
mm with a range of 6-8 mm, and P. guajava L. HE had an average 
measurement of 6.12 mm with a range of 6-8 mm for the P. aeruginosa 
strains tested. 
The 62% Ethanol had an average measurement of 6.19 mm with a range of 


































































































a range of 6-10 mm. As the tinctures are prepared in alcohol, the ethanol 
inhibition is taken into account to determine the effectiveness of a tincture 
on P. aeruginosa. 
 
Figure 4. 4 Graphical representation the tinctures and alcohol measurements 
from the Kirby-Bauer Disk Diffusion method, indicating the median, 
different measurements and outliers. 
The mother tincture was prepared in 62% ethanol and results are compared 
to the 62% ethanol results. The herbal extract and 3cH potency was 
prepared in 50% and 45% ethanol respectively, and the results were 
compared to the 50% ethanol results. To compensate for the effect of 
ethanol inhibition, the results are subtracted from the tincture results. 
As can be seen from the graph, P. guajava Ø had an inhibition zone range 
that was more than could be accounted for than the effect of the 62% 
ethanol alone. This indicates that the P. guajava Ø had an inhibitory action 

































































inhibitory action on P. aeruginosa. This will be discussed further in Chapter 
5. 
4.2 Minimum Inhibitory Concentration (MIC) 
The MIC was testing was done to 1) confirm the results from the Kirby-Bauer 
disc diffusion test and 2) to determine what minimum concentration of the 
tincture would be able to inhibit the growth of the P. aeruginosa strains 
tested.  
The same environmental strains were used as for the Kirby Bauer disk 
diffusion method using the volumes described in Chapter 3. The test was 
originally performed in 96 well plates (method not described, figure 4.5) but 
was changed to 24 well plates after the first experiment. This was done due 
to the difficulty of determining inhibition if growth was inhibited in the 96 well 
plate with INT dye and the tinctures used. Possible reasons could be the 
impact of the tincture colour on the INT colour produced or the fact that it 
was observed that the P. aeruginosa made a biofilm at the liquid-air 
interphase, as described by Drenkard and Ausubel (2002).  
 
 
Figure 4. 5 Example of the 96 well plates originally used to determine the 
minimum inhibitory concentration of P. guajava Ø, P. guajava 3cH 
and P. guajava HE, showing the difficulty with interpretation. 




Inhibition of the P. aeruginosa strains was better observed as seen in figure 
4.6 and allowed better colour differentiation to determine the MIC. Dilutions 
were taken to 3 wells instead of 6 wells as it was noticed that colour changes 
in the wells in the 96 well plate occurred quickly after the first dilution.  
 
Figure 4. 6 Example of the 24 well plates used to determine the minimum 
inhibitory concentration of the homoeopathic tinctures and herbal 
extract tested. 
The presence of biofilms was again noticed in figure 4.6 created by P. 
aeruginosa and the biofilms had to be punctured, as can be observed, to 
perform the Minimum Bactericidal Concentration. Biofilms are created in 
response to changes in the environment and are a result of phenotypic 
variation in P. aeruginosa and other Gram-negative bacteria (Drenkard and 
Ausubel, 2002; Lai et al., 2009). Biofilm formation creates bacterial 
resistance in that the antimicrobial agent cannot penetrate the 
exopolysaccharide matrix (Chakotiya et al., 2016). This will all be discussed 
further in detail in Chapter 5. 
The results obtained from the Minimum Inhibitory Concentration is 
summarized over all the strains in Table 4.1. The dilution (x) indicates the 
last concentration at which total bacterial inhibition was observed i.e. no 




colour change (remains clear). The alcohol controls were taken into account 
and the solvent effect was subtracted from the alcohol effect to give a more 
accurate result of the solvents activity for growth inhibition. The results per 
strain are in Appendix H. 
The P. guajava Ø performed better across all the strains by inhibiting more 
strains but the P. guajava L. HE inhibited up to the second dilution in a few 
strains even if it inhibited less strains overall. 
Table 4. 1 Summary of the MIC results of P. guajava L. HE, P. guajava Ø and 
P. guajava 3cH potency against all strains tested of P. aeruginosa. 
The data given is at the dilution factor that inhibited growth, and is 
indicated as a percentage of all strains tested. 
Test Dilution factor done in triplicate 
P. guajava Ø in 62% EtOH 50% at 2x 
P. guajava 3cH potency in 45% EtOH 19.2% at 2x, 3.9% at 4x 
P. guajava L. HE in 50% EtOH 42.3% at 2x, 26.9% at 4x 
Streptomycin HLS 300 76.9% at 2x, 7.7% at 4x 
 
The results obtained in MIC are different to the Kirby-Bauer Disk Diffusion 
method. This could be because more tincture was added to the wells than 
was used to inoculate the disks in MIC. Another factor could be that in MIC, 
the P. aeruginosa was forced to be in contact with the tincture at all times 
and as such created a biofilm to protect itself, whereas in the Kirby-Bauer 
Disk Diffusion method, P. aeruginosa could move away from the stimulus 
by using the efflux pumps and swarming (Drenkard and Ausubel, 2002; Lai 
et al., 2009; Chakotiya et al., 2016). 
4.3 Minimum Bactericidal Concentration (MBC) 
To determine if the tincture resulted in the death of the bacterial cells, the 
MBC experiments were performed. This is important as this study was to 
determine the antimicrobial activity of P. guajava L. HE, P. guajava Ø and 




P. guajava 3cH potency and without MBC, it cannot be determined if the 
tinctures only inhibit P. aeruginosa or if they are truly effective in killing the 
bacteria (Lai et al., 2009).  
Samples from the wells from the 24 well plates (figure 4.6) were grown 
overnight and plated onto Mueller-Hinton agar plates to determine if the 
bacteria would regrow when placed on a nutrient-rich medium. Figure 4.7 
below shows a Mueller-Hinton agar plate that was streaked with cells from 
the wells in figure 4.6 to confirm the presence of viable cells after treatment 
of the P. aeruginosa cells. Regrowth on a Mueller-Hinton agar plate 
indicates that the tincture had bacteriostatic effect, no regrowth indicates 
that the tincture was bactericidal. The results obtained is summarised in 
Table 4.2 but all the result photos are in Appendix I and the detailed results 
are tabulated in Appendix J. 
 
Figure 4. 7 Photo of the Mueller-Hinton agar plates that were streaked with cells 
from the wells in Figure 4.2 to confirm the presence of viable cells 
after treatment of the P. aeruginosa cells with P. guajava L HE, P. 
guajava Ø and P. guajava 3cH potency. 
The results indicate, overall, that the tinctures and antibiotics were more 
bacteriostatic than bactericidal. Only a small percentage of the results 
showed bactericidal activity. This indicates that P. aeruginosa is MDR and 
that the efflux pumps, swarming and swimming were very effective in the 
survival of the bacteria (Drenkard and Ausubel, 2002; Lai et al., 2009; 
Chakotiya et al., 2016). 




Table 4. 2 Summary of the results obtained from MIC (Bacteriostatic 
concentration) and MBC (Bactericidal concentration) overall. The 
alcohol controls were taken into account and the solvent effect was 
subtracted from the alcohol effect to give a more accurate result of 
the solvents activity for bacteriostatic and bactericidal activity. 
 Number of strains per dilution 
Test 2x 4x 
P. guajava Ø in 62% EtOH   
Bacteriostatic concentration 16 strains None 
Bactericidal concentration 7 strains None 
62% EtOH bacteriostatic action 3 strains None 
No effect None 26 strains 
P. guajava 3cH potency in 45% 
EtOH 
  
Bacteriostatic concentration 5 strains 1 strain 
Bactericidal concentration 1 strain None 
50% EtOH bacteriostatic action 3 strains None 
No effect 17 strains 25 strains 
P. guajava L. HE in 50% EtOH   
Bacteriostatic concentration 10 strains 7 strains 
Bactericidal concentration 4 strains None 
50% EtOH bacteriostatic 3 strains None 
No effect 9 strains 19 strains 
Streptomycin HLS 300   
Bacteriostatic concentration 12 strains None 
Bactericidal concentration 9 strains 1 strain 
No effect 4 strains 25 strains 
 
  




4.4 Agar Overlay Disk Diffusion Method 
The Agar Overlay Disk Diffusion method was performed to confirm the 
results from the Kirby-Bauer Disk Diffusion method. The difference with this 
method is that the bacteria is in the agar overlay and should be more 
susceptible to the effects of the tincture.  
Only 5 strains of Pseudomonas aeruginosa were selected. These strains 
showed the most prominent double growth zones in the Kirby-Bauer Disk 
Diffusion method. Figure 4.8 shows a photo of the one the Mueller-Hinton 
Agar plates with the Agar Overlay method and that the P. aeruginosa strain 
in this picture still created a slight halo around the disks indicating the 
inhibition of growth of the cells without the double growth pattern observed 
with the Kirby-Bauer Disk Diffusion method.  
 
 
Figure 4. 8 Photo of the Agar Overlay Disk Diffusion method where P. 
aeruginosa is in the overlay agar placed over the disks instead of 
as a lawn that the disks are placed onto. The disks are 1) P. 
guajava Ø in 62% EtOH, 2) P. guajava 3cH potency in 45% EtOH, 
3) P. guajava L. HE in 50% EtOH, 4) 62% EtOH, 5) 50% EtOH, 6) 









Of the 5 strains tested, P. guajava Ø and P. guajava L. HE showed a halo 
in 3 of the 5 strains, P. guajava 3cH and alcohol controls showed a halo in 
1 out of the 5 strains. The antibiotic control showed a small halo in 2 of the 
5 strains. The complete pictures of the results are in Appendix K. Chapter 5 
will discuss these results in more detail. 
4.5 Erlenmeyer Flask method 
The Erlenmeyer Flask method was done to determine if biofilm formation at 
the air-liquid interface could be prevented with the shaking incubator set to 
a higher speed. The higher speed would prevent P. aeruginosa from being 
able to form an attachment to the surface of the container as well as to each 
other. The shaking would also prevent or drastically minimise swimming and 
swarming away from the tinctures in an attempt to save itself (Drenkard and 
Ausubel, 2002; Lai et al., 2009; Chakotiya et al., 2016). 
It was found that this method did prevent P. aeruginosa from developing a 
biofilm and thus the tinctures were more effective. The results are 
summarised in Table 4.3 below.  
Table 4. 3 Summary of the results obtained from Erlenmeyer Flask method. 
The “+” indicates growth and “-“ indicates no growth. 
 Strain 
Test compound PAT6 Pat11 B6/28 ATCC B5/17 
Media - - - - - 
P. guajava Ø in 62% EtOH - - - - - 
P. guajava 3cH potency in 45% EtOH - - - - - 
P. guajava L. HE in 50% EtOH - - - - - 
62% EtOH - - - + + 
50% EtOH + - - - - 
Antibiotic - - - - + 
Bacteria and media + + + + + 




The flasks were plated out onto grids to determine MBC. Figure 4.8a and b 
shows a photo of one of the Erlenmeyer flasks and Figure 4.9 shows the 
MBC results of the Erlenmeyer flask method.  
   
Figure 4. 9 A photo of the MBC results from plating out the Erlenmeyer flasks 
together with the corresponding grid template.  
From Figure 4.9, it can be seen that in quadrant D, all the blank controls 
were negative for growth, and shows that no contamination occurred of the 
broth. In quadrant C, PAT6 had growth showing inhibition and not 
bactericidal action for alcohol controls. Also in quadrant C, B5(17) showed 
no growth for the alcohol controls. Quadrant B showed growth for the ATCC 
strain of P. aeruginosa for the antibiotic control but no growth for the 
tinctures. Quadrant A showed growth for the alcohol controls of PAT11, but 
no growth for the tinctures.  
The results are summarized in Table 4.4. These results indicate that the 
tinctures had bactericidal effect on the strains and alcohol did not have the 








Table 4. 4 Summary of the results obtained from the MBC of the Erlenmeyer 
Flask method. The “+” indicates growth and “-“ indicates no growth. 
 Strain 
Test compound PAT6 Pat11 B6/28 ATCC B5/17 
Media - - - - - 
P. guajava Ø in 62% EtOH - - - - + 
P. guajava 3cH potency in 45% EtOH - - - - + 
P. guajava L. HE in 50% EtOH - - - - - 
62% EtOH + - - + + 
50% EtOH + - - - + 
Antibiotic + + - + + 
Bacteria and media + + + + + 
 
The results obtained will be discussed in more detail in the next chapter. 
  





5. DISCUSSION OF RESULTS 
5.1 Kirby-Bauer disk diffusion method 
The antimicrobial effects of Psidium guajava herbal extract, Psidium 
guajava mother tincture and Psidium guajava 3cH potency were measured 
by the degree to which the compounds inhibited P. aeruginosa bacterial 
growth. The disks used were 6mm in diameter and all measurements thus 
shown as 6mm showed no bacterial growth inhibition. The experiments 
were conducted in triplicate and each disk was measured twice for precision 
and reliability of the data. The mean for each measurement was calculated 
and used as the zone of inhibition for every disk.  
As seen in Figure 4.3, P. guajava Ø appears to have the most antibacterial 
effect against P. aeruginosa with a median reading of 6.41mm. However, in 
Figure 4.4 it can be seen that most of the strains showed no effect to P. 
guajava Ø when the 4 outliers are not taken into account. The 4 outliers 
influenced the median and a false positive was indicated for the inhibition of 
P. aeruginosa by P. guajava Ø.  
From the detailed results in Appendix E, P. guajava Ø had an 11,5% 
inhibition activity against 26 strains that were repeated 3 times, when the 
outliers are taken into account. This percentage drops to 5,1% when the 
outliers are not taken into consideration. This is not a high inhibition activity 
and indicates that the P. guajava Ø was not as effective as the antibiotic 
used in inhibiting P. aeruginosa.  
Figure 4.3 shows that P. guajava 3cH potency showed some antibacterial 
effect against P. aeruginosa but not as much as P. guajava Ø (which had 
outliers affecting the median). From the detailed results in Appendix E, P. 
guajava 3cH had a 20.5% inhibition activity against the 26 strains that were 
repeated 3 times. There were no outliers for P. guajava 3cH. This is still not 




a high inhibition activity, but indicates more effectiveness in inhibition of P. 
aeruginosa for P. guajava 3cH than P. guajava Ø. P. guajava L. HE did not 
show much antibacterial effect against P. aeruginosa with 10.3% 
effectiveness for inhibition. Further studies could be done to determine if P. 
guajava Ø, P. guajava 3cH potency and P. guajava L. HE administered at 
a stronger dose or consecutive doses over a period of a few days would 
have a stronger antibacterial effect on P. aeruginosa.  
Many of the Kirby-Bauer plates showed an unusual pattern of inhibition for 
the tincture and herbal extract, as seen in Figure 4.2. This could be 
explained by one of two possibilities; either mobility of the P. aeruginosa or 
the use of efflux pumps to reduce the effects of the tincture. According to 
several studies done by Metwally et al., (2011) and Sriwilaijaroen et al., 
(2012) this could be due to five flavonoids which include tannins, gallic acid 
and catechin that are present in the leaves (Anand et al., 2016). Tannin 
inhibits extracellular microbial enzymes or may have a direct impact on 
microbial metabolism by inhibiting oxidative phosphorylation (Scalbert, 
1991; Maisetta et al., 2019). Gallic acid’s mechanism of action is the 
disruption of the cell membrane or pore formation in the cell membrane 
which leads to the leakage of the intracellular contents (Borges et al., 2013). 
Catechin’s antibacterial action is by damaging the bacterial cell membrane 
and causing leakage cell contents as well as inhibiting bacterial DNA gyrase 
(Coşarcă et al., 2019). 
The first option as mentioned is P. aeruginosa’s ability of swarming and 
swimming motility. Although P. aeruginosa is generally monoflagellated, it 
is capable of having the flagella as well as additional Type IV pili. These are 
appendages that modulate attachment of P.  aeruginosa to solid surfaces 
and  are an adaptation for survival in response to stressors as it  makes the 
bacteria very motile (Harshey, 2003; Tsang et al., 2003; Tremblay, et al., 
2007; Lai et al., 2009; Caveney et al., 2020). P. aeruginosa uses swarming 
for surface colonisation and swimming for biofilm formation as well as 
surface colonisation (Harshey, 2003; Lai et al., 2009). P. aeruginosa also 




produces biosurfactants which help it to migrate over more solid surfaces 
by creating a slippery or slimy surface for it to migrate over (Harshey, 2003; 
Tremblay et al., 2007).  
The second, and more likely option, may be due to the efflux pumps of P. 
aeruginosa. P. aeruginosa has four efflux pumps; namely MexAB-OprM, 
MexCD-OprJ, MexEF-OprN and MexXY which are often found to be up-
regulated in clinical isolates. MexAB-OprM is a very important efflux pump 
as is expresses and provides intrinsic resistance to a wide spectrum of 
antibiotics (Rampioni et al., 2017; Shrestha et al., 2020). 
When P. aeruginosa is exposed to a stimulus, as was done in Lai et al., 
(2009), the efflux pumps are activated and the bacteria actively pumps out 
the stimulus and begins to migrate away from the stimulus due to 
chemotaxis. This creates the first ring that is noticeable as it is at the highest 
concentration. This mechanism was tested by Lai and co-workers (2009) 
with various different stimuli including heavy metals. The migration away 
from the stimulus is possible as P. aeruginosa is flagellated and  motile 
(Tsang et al., 2003; Tremblay et al., 2007; Caveney et al., 2020). The same 
mechanism was observed with P. guajava Ø, P. guajava 3cH and P. 
guajava L. HE. The double ring could also be due to the efflux pumps being 
activated and actively pumping out the stimulus until the stimulus is no 
longer a threat. The bacteria then begin to grow, but once the stimulus has 
reached the ring of growth that has formed over time, it becomes 
bacteriostatic and a second ring is formed (Shrestha et al., 2020).  
The migration is called swarming. Swarming occurs by the rapid and 
coordinated migration of highly differentiated swarm cells on a semi-solid 
surface (Tremblay, et al., 2007; Lai et al., 2009). P. aeruginosa does this in 
an attempt to save itself and to survive (Swiecicki et al., 2013; Tremblay, et 
al., 2007). P. aeruginosa shows the migration away from a stimulus 
(Appendix D) and as summarized in a table in Appendix E. Since P. 
aeruginosa was not in a liquid medium, as it was on a plate, for the Kirby-




Bauer disk diffusion method, it could not swim away from the stimulus, but 
rather swarmed away and used the efflux pumps to move away from the 
stimulus (Tremblay, et al., 2007; Lai et al., 2009; Caveney et al., 2020; 
Shrestha, et al., 2020) P. guajava Ø showed this trend in 9 of the 26 strains, 
P. guajava 3cH in 12 of the 26 strains, and P, guajava L. HE in 6 of the 26 
strains. Swarming and the efflux pumps are the main reasons why P. 
aeruginosa is a ‘super-bug’ and is MDR. Once the initial stress reaction has 
occurred and the stimulus is of a lesser concentration, the efflux pumps 
don’t have to work as hard as they initially did, and the second ring is 
observed. The bacteria’s efflux pumps will continue working until it is in a 
zone where there is no more stimulus that threatens its survival and the 
efflux pumps downregulate and become dormant again (Lai et al., 2009). 
Lai et al., (2009) proved that if a new stimulus is introduced into the zones 
where no stimulus is found, P. aeruginosa will activate its efflux pumps 
again and swarm away from the stimulus. 
A further study was undertaken by ‘reversing’ the Kirby-Bauer disk diffusion 
method to the Agar Overlay Disk Diffusion method to determine if P. 
aeruginosa would still activate the efflux pumps and swarm away from 
stimulus. This will be discussed in section 5.4. 
5.2 Minimum Inhibitory Concentration (MIC) 
Biofilms are made possible by flagellated Gram-negative bacteria due to 
phenomenon of swimming. The bacteria swim away from a stimulus or 
antibiotic towards each other so that they may survive by creating biofilms 
(Tremblay et al., 2007). Bacterial biofilms consist of dense microcolonies 
that attach strongly to each other as well as to surfaces and are encased in 
a self-manufactured protective exopolymeric matrix or sheath that allows 
the bacteria to survive antimicrobial agents at concentrations that are a 
thousand times higher than a free-living bacteria can withstand (Drenkard 
and Ausubel, 2002; Mikkelsen et al., 2007; Lai et al., 2009; Chakotiya et al., 
2016).  




It was observed in this study that P. aeruginosa formed biofilms in the wells. 
The biofilm can be observed in Figure 4.6 as well as in Appendix G. When 
the INT dye was added, the colour change occurred on top of the biofilm 
and the biofilm had to be punctured in order to sample the planktonic cells 
underneath the biofilm. The formation of the biofilm indicates the swimming 
phenomenon of P. aeruginosa (Tremblay, et al., 2007), as well as that the 
bacteria is capable of producing a protective sheath to protect itself from 
stimulus (Drenkard and Ausubel, 2002; Mikkelsen, et al., 2007; Lai et al., 
2009; Chakotiya et al., 2016). The impact of the formation of a biofilm in 
regards to antibiotics is of importance as P. aeruginosa has the ability to 
adapt to different environments and stimuli (Lai et al., 2009) and thus makes 
it MDR and poses a threat to the immunocompromised individual (Strateva 
and Yordanov, 2009; Rasamiravaka et al., 2015;  Chakotiya et al., 2016; 
Moradali, Ghods and Rehm, 2017).   
Biofilms are made up of two cells; adherent cells and persister cells with 
free moving planktonic cells found in the liquid. Persister cells are found at 
the liquid-air interface and make up the biofilm. Persister cells are different 
to planktonic in the way that they express their genes. They resemble each 
other when the persister cells are dormant and are of a higher concentration 
than the planktonic cells in biofilm creation and also more metabolically 
active (Mikkelsen et al., 2007). These cells are not affected by antibiotics or 
are less sensitive to antibiotics as they become dormant when there is a 
high concentration of antibiotics, and once the antibiotics level drops to low, 
they reactivate and will regrow. Persister cells account for the resurgence 
in infections where biofilms are created causing severe chronic infections 
(Mikkelsen et al., 2007; Wood et al., 2013; Yu et al., 2019). 
Biofilms are created in response to changes in the environment and are a 
result of phenotypic variation in P. aeruginosa and other gram-negative 
bacteria (Drenkard and Ausubel, 2002; Tremblay et al., 2007; Lai et al., 
2009; Shrestha et al., 2020). Biofilm formation creates bacterial resistance 
in that the antimicrobial agent cannot penetrate the exopolysaccharide 




matrix due to the presence of persister cells (Chakotiya et al., 2016). 
Swarming and biofilm formation both contribute the MDR of P. aeruginosa 
and the correlation between the two are still being investigated (Drenkard 
and Ausubel, 2002; Harshey, 2003; Lai et al., 2009; Chakotiya et al., 2016; 
Shrestha et al., 2020). 
The results for this study, summarized in Table 4.1 and per strain in 
Appendix H, show that it was not clear if the tinctures were effective in 
inhibiting P. aeruginosa because they survived as biofilms. This created a 
“clean” liquid phase due to the fact that most of the cells had ‘swam’ away 
from the tincture in the media below to create the biofilm at the liquid-air 
interphase and that the majority of the bacteria was encased within the 
biofilm. Further experiments were performed to determine if the tincture and 
extract could be bacteriostatic or bactericidal when the cells were placed in 
an environment where they could not form biofilms thus keeping the media, 
bacteria and tincture/ extract in constant contact with each other. This will 
be discussed in section 5.5. 
5.3 Minimum Bactericidal Concentration (MBC) 
It is noted that when the samples were extracted from the wells of the MIC 
experiments for plating out, the inoculation loop punctured the biofilm into 
the liquid beneath and as such samples from both the biofilm and the liquid 
was collected at the same time. The results obtained for the MBC is thus a 
mixture of planktonic- (free cells in liquid), adherent- (cells in biofilm) and 
persistent cells (cells at liquid-air interphase), again making judgement on 
the effectiveness of the tinctures difficult. Especially the persister cells in the 
biofilm could have been dormant in MIC experiments but once the tincture/ 
extract were removed, the cells reactivated and started replicating and 
growing again (Mikkelsen et al., 2007; Wood et al., 2013; Yu et al., 2019). 
This can be seen in Figure 4.7. All result pictures are in Appendix I. In further 
studies it is suggested to first separate the biofilm and liquid phases to test 
where active cells are.  




In this study the P. guajava Ø performed better that the other two tinctures 
at the first dilution, with P. guajava 3cH and P. guajava L. HE only having 
bacteriostatic effect at the second dilution (4x).  Streptomycin was effective 
in inhibiting the strains and with the low bactericidal outcome; it indicates 
that the strains used for this study were antibiotic resistant. The possibility 
that the bacterial cells had migrated or swam towards the liquid-air interface, 
away from the tincture/ extract and created a biofilm is visible and by doing 
so, most bacterial cells survived. This is evident from the results 
summarized in Table 4.2 as well as the summary of results from MIC and 
MBC in Appendix J.  
Due to the bacteria’s biofilm creation and swimming, follow-up tests were 
done and will be discussed in section 5.5. 
5.4 Agar Overlay Disk Diffusion Method 
Five strains were selected that showed the double zones clearly in the 
Kirby-Bauer method from section 5.1 to test  this method. A soft agar was 
used for the overlay in this method with the bacteria suspended within the 
overlay. The reason for this is to prevent the bacteria from being able to 
swarm away from the treatments and to determine if the zone of inhibition 
is caused by the use of the efflux pumps of P. aeruginosa (Hockett and 
Baltrus, 2017). 
Of the five strains, P. guajava Ø and P. guajava L. HE showed a halo in 3 
of the 5 strains, P. guajava 3cH and alcohol controls showed a halo in 1 out 
of the 5 strains. The antibiotic control showed a small halo in 2 of the 5 
strains. No double ring was visible on any of the plates indicating that P. 
aeruginosa could not swarm away from the tincture/ extract or antibiotic, but 
could potentially only use the efflux pumps, or some other method of 
avoiding the effects of the tinctures. Further studies should be done with the 
agar overlay method and different thicknesses of overlay that will optimize 
results and determine whether this method is effective as well as using all 
the strains that were initially used in this study. 




5.5 Erlenmeyer Flask method 
Because the P. aeruginosa strains kept on producing biofilms at the air-
liquid interphase, it was decided to do one experiment forcing the cells to 
stay in the liquid phase to test if the treatments actually had an effect on any 
of the cells. This was achieved by growing the cells in Erlenmeyer flasks 
with rotary agitations at 200 rpm’s. The hypothesis was that with the 
continual shaking of the Erlenmeyer flasks during incubation, biofilm 
formation would be prevented by minimizing P. aeruginosa’s ability to swim 
in a liquid medium and to migrate away from a stimulus and attach to each 
other to form a biofilm and would give a true reflection of the bactericidal 
and bacteriostatic effect (Drenkard and Ausubel, 2002; Lai et al., 2009; 
Chakotiya et al., 2016). 
The same five strains that were used in the Agar Overlay Disk Diffusion 
method were used again in this method to determine if the results from MIC 
could be confirmed or not. From the results obtained for the five strains, the 
tincture and extract had a bacteriostatic effect on one strain (strain B5/17) 
and bactericidal activity on the remaining four stains.  
The reason for the difference in results between MIC and the Erlenmeyer 
flask method could be that since no biofilm was formed, and the true effect 
of the tincture and extract on the bacterial cells was determined. When 
remaining suspended in the media and separate from each other, P. 
aeruginosa can not form a protective exopolymeric matrix or sheath and 
protect itself from a stress stimulus (Drenkard and Ausubel, 2002; Mikkelsen 
et al., 2007; Lai et al., 2009; Chakotiya et al., 2016).  
This observation has an impact on the way P. aeruginosa cells should be 
tested and how results should be interpreted. The tincture and extract 
clearly have an effect on the P. aeruginosa cells but may be more effective 
in the human body when used in conjunction with compounds that inhibit 
biofilm formation (Chen et al., 2018) or even efflux pumps that have recently 
been linked to biofilm formation in Gram-negative bacteria (Alav et al., 




2018). Either of these would keep the P. aeruginosa cells unattached 
increasing the likelihood of the tinctures working.  
  





6. CONCLUSION AND RECOMMENDATIONS 
6.1 Conclusion 
The results of this study demonstrated that P. guajava Ø, P. guajava 3cH 
and P. guajava L. HE could potentially have bactericidal or bacteriostatic 
effects on the P. aeruginosa strains. This is however subject to  the correct 
in-vitro method being utilised. The ability of P. aeruginosa to use 
physiological processes such as complex chemosensory systems, efflux 
pumps and biofilm formation to avoid the tincture and extract antimicrobial 
effect with the Kirby-Bauer Disk Diffusion and MIC methods makes 
determining its true effect difficult. By ‘forcing” cells to not form biofilms is a 
more realistic method to observe the true effect of the tincture/extract, 
indicating that these treatments are therefore more likely to only be effective 
against planktonic P. aeruginosa cells, i.e. free flowing bacteria in 
suspension.  
It was hypothesized that the herbal extract, homeopathic mother tincture 
and 3cH potency of Psidium guajava L. would show antimicrobial actions 
against multidrug resistant Pseudomonas aeruginosa by inhibiting the 
growth of the organisms on solid and in liquid culture media. This hypothesis 
was supported by this study in that Psidium guajava L herbal extract, 
homeopathic mother tincture and 3cH potency showed antimicrobial actions 
and surfing against Pseudomonas aeruginosa in the different methods 
used.  
6.2 Recommendations  
Based on the results from this study the following studies can be considered 
in future: 




● The Erlenmeyer flasks experiments should be done on the remaining 
21 strains of the 26 P. aeruginosa cells. It was only tested on five 
strains to test a hypothesis.  
● Studies should be performed to test the effectiveness of the P. 
guajava  tinctures and herbal extracts on the planktonic, persistent 
and adherent P. aeruginosa cells. 
● Studies could be included on the combined effect of P. guajava 
tincture and herbal extract, when applied with biofilm inhibiting 
compounds and antibiotics. 
● Studies should be done to better understand what mechanisms (i.e. 
efflux pumps, swimming, swarming etc.) is used by P. aeruginosa 
cells in the presence of P. guajava  tincture and herbal extract.  
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APPENDIX D (continued)          Pictures of Kirby-Bauer Results 
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APPENDIX D (continued)          Pictures of Kirby-Bauer Results 
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APPENDIX D (continued)          Pictures of Kirby-Bauer Results 
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Summary of the results obtained per strain. 
Key  
1 P. guajava Ø in 62% EtOH 
2 P. guajava 3cH potency in 45% EtOH 
3 P. guajava L. HE in 50% EtOH 
4 62% EtOH 
5 50% EtOH 
6 Streptomycin HLS 300 
 
 Zone of inhibition in mm 
Plate number Strain n 1 2 3 4 5 6 
PS1 PAT13 3 6 6.7 6 6 6 27 
PS2 PAT17 3 6 6 6 7.3 6 26.7 
PS3 PAT18 3 6 6 6 6 6.3 27 
PS4 PAT20 3 6 6 6 6 6 26.7 
PS5 PAT22 3 6 6 6 6.3 6 27.7 
PS6 PAT23 3 6.3 6.3 6 6 7.3 28 
PS7 B5(17) 3 6.3 6 6.3 7.3 6.3 24.3 
PS8 B5(201) 3 7 6.7 7 6.3 6 27.7 
PS9 B5(36) 3 7.3 6 6.7 6 7.3 26.7 
PS10 PAT27 3 6 6 6 6.3 6 18.7 
PS11 B6(28) 3 7.7 6 6.3 6 6 28.7 
PS12 B4(17) 3 7.7 6 6 6 6 27 
PS13 P5 3 7.7 6.3 6 6 6.3 15.3 
PS14 P29 3 6 6.3 6 6 6.3 28 
PS15 B6(53) 3 6.7 6.7 6 6 6 28.7 
PS16 B6(38) 3 6 6 6 6 6 26 
 
  




APPENDIX E (continued)  Summary of the results obtained per strain. 
 
   Zone of inhibition in mm 
Plate 
number 
Strain n 1 2 3 4 5 6 
PS17 PAT10 3 6 6 6 6 6 27 
PS18 PAT1 3 6 6 6 7 6.3 28 
PS19 PAT25 3 6 6 6 6 6 19 
PS20 P. aeruginosa (ATCC® strain 
27853) 
3 7.3 6.3 6.3 6 6 27.3 
PS21 PAT2 3 6 7 6 6 6.3 28 
PS22 PAT6 3 6.7 6.7 6 6 6.3 26.7 
PS23 PAT7 3 6 7.3 6 6 6.7 25 
PS24 PAT8 3 6 7 6.3 6 7 26 
PS25 PAT11 3 6 6 6 6 6 26 
PS26 PAT14 3 6 6.7 6 6 6 15 
 
  





Summary of the overall results obtained 
  Measurement (mm) 
Test n (3 repeats 
per strain for 
26 strains) 
Average Minimum Maximum 
Homeopathic  
P. guajava Ø in 62% 
EtOH 
78 6.41 6 11 
P. guajava 3cH potency in 
45% EtOH 
78 6.31 6 8 
P. guajava L. HE in 50% 
EtOH 
78 6.12 6 8 
Solvents 
62% EtOH 78 6.19 6 10 
50% EtOH 78 6.26 6 10 
Control 
Streptomycin HLS 300 78 25.4 10 30 
 
  





Photos of the results from MIC of the Kirby-Bauer Disk Diffusion method. 
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APPENDIX G (continued)  Photos of the results from MIC of the Kirby-Bauer 
Disk Diffusion method 
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Summary of the MIC results of P. guajava L. HE, P. guajava Ø and P. guajava 3cH 
potency per strain tested of P. aeruginosa. The alcohol controls were taken into 
account and the solvent effect was subtracted from the alcohol effect to give a 
more accurate result of the solvents activity for growth inhibition. The grey blocks 
reflect the results of the solvents that had true inhibitory effect. The data given is 
the dilution factor that inhibited growth. 
























































































PS1 PAT13 2x 2x 4x 2x 2x 2x 
PS2 PAT17 2x 2x 4x 2x 2x 2x 
PS3 PAT18 2x 2x 4x 2x - 2x 
PS4 PAT20 2x 2x 2x 2x 2x 2x 
PS5 PAT22 2x 4x 2x 2x 2x 2x 
PS6 PAT23 2x - 2x - - 2x 
PS7 B5(17) 2x 2x 2x 2x - 2x 
PS8 B5(201) 2x - 2x - - 2x 
PS9 B5(36) 2x 2x 4x - 2x 2x 
PS10 PAT27 2x - 2x 2x 2x - 
PS11 B6(28) 2x - 2x 2x - 2x 
PS12 B4(17) 2x 2x 4x 4x 4x 2x 
PS13 P5 2x - - - - - 
PS14 P29 2x 2x 2x 2x 4x - 
PS15 B6(53) 2x 2x 2x - 2x 2x 
PS16 B6(38) 2x 2x 2x - 2x 2x 
PS17 PAT10 2x - 4x 2x 2x 2x 
 
  




APPENDIX H continued    Summary of the MIC results of P. guajava L. HE, P. 
guajava Ø and P. guajava 3cH potency per strain 
tested of P. aeruginosa. The alcohol controls were 
taken into account and the solvent effect was 
subtracted from the alcohol effect to give a more 
accurate result of the solvents activity for growth 
inhibition. The grey blocks reflect the results of the 
solvents that had true inhibitory effect. The data 
given is the dilution factor that inhibited growth. 
PS18 PAT1 2x 2x 2x - - 2x 
PS19 PAT25 2x - 2x 2x 4x - 
PS20 P. aeruginosa (ATCC® 
strain 27853) 
2x 2x - - 2x 8x 
PS21 PAT2 2x 2x 2x - - 2x 
PS22 PAT6 2x - 4x - - 4x 
PS23 PAT7 2x - 2x 2x - 2x 
PS24 PAT8 2x 2x - - - 2x 
PS25 PAT11 2x 2x 2x - 2x 2x 
PS26 PAT14 2x - 2x - - 2x 
Key 
-  No bacterial inhibition 
 
  





Photos of the results from MBC 
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APPENDIX I (continued) Photos of the results from MBC 
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Summary of the results obtained from MIC (Bacteriostatic concentration) and MBC (Bactericidal concentration) overall. (+ indicates 
growth and – indicates no growth) 
             
 
Mother tincture 
  3ch HE 62% 50% Antibiotic 
  B1 B2 C1 C2 D1 D2 A4 A5 B4 B5 C4 C5 
PS1 - + + + - + + + + + - + 
PS2 - + + + + + + + + + + + 
PS3 + + + + + + + + + + + + 
PS4 - + - + - + + + +  + - + 
PS5 + + + + + + + + + + + + 
PS6 + + + + + + + + + + + + 
PS7 + + + + + + + + + + + + 
PS8 + + + + + + + + + + - + 
PS9 + + + + + + + + + + + + 
PS10 + + + + + + + + + + + + 
PS11 - + + + + + + + + + - + 
PS12 - + + + + + + + + + - + 
PS13 + + + + + + + + + + + + 
PS14 - + - + - + - + - + - + 
 




APPENDIX J (continued)  Summary of the results obtained from MIC (Bacteriostatic concentration) and MBC (Bactericidal 
concentration) overall. (+ indicates growth and – indicates no growth) 
             
 
Mother tincture 
  3ch HE 62% 50% Antibiotic 
  B1 B2 C1 C2 D1 D2 A4 A5 B4 B5 C4 C5 
PS15 - + + + - + + + + + - + 
PS16 - + + + - + + + - + - + 
PS17 - + - + - + - + - + - + 
PS18 + + + + + + + + + + + + 
PS19 - + + + + + - + + + + + 
PS20 + + + + - + + + + + - - 
PS21 + + + + + + + + + + + + 
PS22 + + + + + + + + + + + + 
PS23 + + + + + + + + + + + + 
PS24 + + + + + + + + + + + + 
PS25 + + + + + + + + + + + + 










Photos of the Agar Overlay Disk Diffusion method 
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